



HIV DRUG RESISTANCE

CLINIC-BASED SURVEY OF ACQUIRED HIV DRUG RESISTANCE

AUGUST 2021



World Health
Organization

HIV DRUG RESISTANCE

**CLINIC-BASED SURVEY
OF ACQUIRED HIV
DRUG RESISTANCE**

AUGUST 2021

Clinic-based survey of acquired HIV drug resistance

This publication is the update of the document published in 2014 entitled *Surveillance of HIV drug resistance in adults receiving ART (acquired HIV drug resistance)*

ISBN 978-92-4-003500-3 (electronic version)

ISBN 978-92-4-003501-0 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Clinic-based survey of acquired HIV drug resistance. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Layout by ACW, London

CONTENTS

ACKNOWLEDGEMENTS	v	A2.1.5 Determining the number of clinics to sample	23
ABBREVIATIONS AND ACRONYMS	vi	A2.2 Anticipated precision in the ADR estimates	23
DEFINITIONS	vii	A2.3 Analysis	24
EXECUTIVE SUMMARY	viii	A2.3.1 Notation	24
1. INTRODUCTION	1	A2.3.2 Calculation of survey sampling weights	25
2. SURVEY METHODS	2	A2.3.2.1 Calculation of survey sampling weights for the survey in adults	25
2.1 OVERVIEW	2	A2.3.2.2 Calculation of survey sampling weights for the survey in children and adolescents	25
2.2 SURVEY OUTCOMES	3	A2.3.3 Analysis for outcomes 1 and 2	26
2.3 ELIGIBILITY CRITERIA	3	A2.3.4 Analysis for outcome 3	27
2.3.1 Inclusion criteria	3	A2.3.5 Analysis for outcomes 4 and 5	28
2.3.2 Exclusion criterion	3	A2.4 Stata code	31
2.4 SURVEY SAMPLE SIZE	4	A2.4.1 Stata code for the survey in adults	31
2.4.1 Sample size design parameters	4	A2.4.1.1 Import viral load laboratory and patient-level data into Stata	31
2.4.2 Allocating samples across strata	4	A2.4.1.2 Import HIV drug resistance data into Stata	32
2.4.3 Adjusting sample sizes for clustering	4	A2.4.1.3 Prepare national-level data	33
2.4.4 Sample size inflation for viral load testing failure and imperfect weights	5	A2.4.1.4 Prepare clinic-level data	33
2.4.5 Precision of the acquired drug resistance estimates	7	A2.4.1.5 Prepare patient-level data on ARV drug treatment regimen	33
2.5 SAMPLING PROCEDURES	7	A2.4.1.6 Prepare patient-level data on other variables	34
2.6 SURVEY OF ACQUIRED HIV DRUG RESISTANCE AMONG CHILDREN AND ADOLESCENTS	7	A2.4.1.7 Merge all data sets	34
2.7 SAMPLING SMALL CLINICS	10	A2.4.1.8 Create survey weights and other necessary variables and declare survey design	35
2.8 REGIONAL REPRESENTATION	10	A2.4.1.9 Analysis for outcomes 1 and 2	35
2.9 OBSERVED SAMPLE SIZE	10	A2.4.1.10 Analysis for outcome 3	36
2.10 DATA ANALYSIS	10	A2.4.1.11 Analysis for outcomes 4 and 5	36
3. IMPLEMENTATION CONSIDERATIONS	11	A2.4.2 Stata code for the survey among children and adolescents	37
3.1 DURATION OF THE SURVEY, PATIENT SCREENING AND SAMPLING	11	A2.4.2.1 Import viral load laboratory and patient-level data into Stata	37
3.2 LIST OF VARIABLES TO BE COLLECTED	11	A2.4.2.2 Import HIV drug resistance data into Stata	38
3.3 REPEATING THE SURVEY	13	A2.4.2.3 Prepare national-level data	38
3.4 DATA EXTRACTION	13	A2.4.2.4 Prepare clinic-level data	39
3.5 REPORTING DATA	13	A2.4.2.5 Prepare patient-level data on ARV drug treatment regime	39
3.6 IMPLEMENTATION OVERVIEW: PRACTICAL GUIDE	14	A2.4.2.6 Prepare patient-level data on other variables	39
4. REFERENCES	15	A2.4.2.7 Merge all data sets	40
ANNEX 1. SELECTING THE CLINICS TO SURVEY	16	A2.4.2.8 Create survey weights and other necessary variables and declare survey design	40
A1.1 Systematic sampling of clinics	16	A2.4.2.9 Analysis for outcomes 1 and 2	41
ANNEX 2. STATISTICAL METHODS	18	A2.4.2.10 Analysis for outcome 3	42
A2.1 Determining the target sample sizes, overall and for individuals receiving DTG-containing regimens	19	A2.4.2.11 Analysis for outcomes 4 and 5	42
A2.1.2 Adjusting sample sizes for clustering	20	ANNEX 3. EXAMPLE: SAMPLE SIZE CALCULATIONS USING THE METHODS DESCRIBED IN SECTION 2.4	43
A2.1.2.1 Options for adjustment of clustering	20	ANNEX 4 BUDGET CONSIDERATIONS	46
A2.1.2.2 Estimating the intracluster correlation	20		
A2.1.3 Sample size inflation for viral load testing failure and imperfect weights	22		
A2.1.4 Determining country-specific per-clinic sample sizes by regimen	22		

ACKNOWLEDGEMENTS

Silvia Bertagnolio (World Health Organization (WHO) Department of Global HIV, Hepatitis and STI Programmes) conceived and coordinated the development of this document, in collaboration with Michael R. Jordan (Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, United States of America, and the Levy Center for Integrated Management of Antimicrobial Resistance, Tufts University, Boston, Massachusetts, USA). WHO acknowledges the technical inputs of Bethany Hedt-Gauthier and Stephanie Wu (Harvard University, Cambridge, Massachusetts, USA), who developed the statistical methods. WHO acknowledges the technical inputs of Amalia Giron and Seth Inzaule (consultants, WHO Department of Global HIV, Hepatitis and STI Programmes). WHO thanks Juliana Da Silva, Sherry Pals, Elliot Raizes and Amitabh Suthar (United States Centers for Diseases Control and Prevention), Fatim Cham (WHO Regional Office for Africa) and Giovanni Ravasi (Pan American Health Organization) for their technical inputs to the initial draft of the document and the members of the WHO HIVResNet Technical Working Group on Surveillance and Monitoring – Chris Archibald, Santiago Avila, Emiliano Bisso, Mohammad Chakroun, Natalie Dean, David Dunn, Philippe Glaziou, Charles Holmes, Gillian Hunt, Derval Igoe, Mathieu Maheu-Giroux, Urvi Parikh, Andrew Phillips, Steve Reynolds – for their contributions.

ABBREVIATIONS AND ACRONYMS

ADR	acquired drug resistance
ART	antiretroviral therapy
ATV/r	atazanavir/ritonavir
CI	confidence interval
DBS	dried blood spot
DE	design effect
DRV/r	darunavir/ritonavir
DTG	dolutegravir
EFV	efavirenz
HIV	human immunodeficiency virus
HIVDR	HIV drug resistance
ICC	intracluster correlation
INI	integrase inhibitor
LPV/r	lopinavir/ritonavir
NRTI	nucleoside reverse-transcriptase inhibitor
NNRTI	non-nucleoside reverse-transcriptase inhibitor
NVP	nevirapine
PI	protease inhibitor
PI/r	ritonavir-boosted protease inhibitor
PPPS	probability proportional to proxy size
PR	protease
/r	with ritonavir boosting
RT	reverse transcriptase
SID	survey identification
VL	viral load
VNS	viral non-suppression

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23597

